Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS.
about
Theiler's virus infection: a model for multiple sclerosisInvolvement of transforming growth factor-beta in regulation of calcium transients in diabetic vascular smooth muscle cellsMedical applications of transforming growth factor-betaThe stem cell secretome and its role in brain repair.Selective immunointervention in autoimmune diseases: lessons from multiple sclerosis.Cytokine-based immunointervention in the treatment of autoimmune diseases.Gene therapy in autoimmune, demyelinating disease of the central nervous system.Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitisTransforming growth factor beta(2) (TGF beta(2)) produces effective pleurodesis in sheep with no systemic complicationsExperimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).Remyelinating and neuroprotective treatments in multiple sclerosis.Immune modulation and increased neurotrophic factor production in multiple sclerosis patients treated with testosterone.MicroRNAs targeting TGFβ signalling underlie the regulatory T cell defect in multiple sclerosis.Toward the development of rational therapies in multiple sclerosis: what is on the horizon?Cytokine Therapies in Neurological Disease.TGF-β signaling is altered in the peripheral blood of subjects with multiple sclerosisTGF-beta enhances effector Th1 cell activation but promotes self-regulation via IL-10.Many cytokines are very useful therapeutic targets in disease.Disease-modifying agents for multiple sclerosis: recent advances and future prospects.Combining genetic mapping with genome-wide expression in experimental autoimmune encephalomyelitis highlights a gene network enriched for T cell functions and candidate genes regulating autoimmunity.Role of cytokines as mediators and regulators of microglial activity in inflammatory demyelination of the CNS.Translational research in neurology and neuroscience 2010: multiple sclerosisPotential impact of B cells on T cell function in multiple sclerosisGarp as a therapeutic target for modulation of T regulatory cell function.TGF-β regulation of encephalitogenic and regulatory T cells in multiple sclerosis.Protection against chemotherapy induced mucositis by TGF-beta(2) in childhood cancer patients: results from a randomized cross-over study.Selective targeting of transforming growth factor-beta1 into TCR/CD28 signalling plasma membrane domains silences T cell activation.Cytokine gene therapy of autoimmune demyelination revisited using herpes simplex virus type-1-derived vectors.HSV-1-mediated IL-1 receptor antagonist gene therapy ameliorates MOG(35-55)-induced experimental autoimmune encephalomyelitis in C57BL/6 mice.Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin.Central nervous system gene therapy with interleukin-4 inhibits progression of ongoing relapsing-remitting autoimmune encephalomyelitis in Biozzi AB/H mice.Cellular localization and expression patterns of interleukin-10, interleukin-4, and their receptors in multiple sclerosis lesions.Comparing transforming growth factor-beta2, talc and bleomycin as pleurodesing agents in sheep.Transforming growth factor-beta1 enhances the interferon-gamma-dependent, interleukin-12-independent pathway of T helper 1 cell differentiation.Reevaluation of Pluripotent Cytokine TGF-β3 in Immunity
P2860
Q24629115-B6ADD3DD-8B72-460D-A5BD-8A173C2BE5EDQ28574951-EF87672E-0BB0-4F66-99F3-089D147207FCQ33723271-DBF901BB-C3EE-48F7-96B2-760DADFC3EA3Q33771698-5DE959CC-F8F6-4898-B1BA-286EDCC46294Q34307160-16D53260-3DC8-4339-8D60-17A763816F53Q35109131-9924EC8C-93F0-4A31-9CDE-541167E63FBBQ35122159-AFB07A09-26F0-4714-A7A4-00E7F19D91B7Q35222027-38658656-C855-4143-8C8F-BA754224B161Q35533555-67312EEC-4A0A-4665-95B3-DB8E4BEAC9D3Q35589934-09775F6A-EA7D-4502-810C-10C38462DAE4Q35753458-4AF7372A-BB14-4F62-9D7E-D61CCFACC363Q36841506-3F7E023E-1611-4D47-818D-6EFE6721D6D7Q36967729-D70E7598-D7F4-4213-BE4C-844DE7E545EEQ36985173-8D623AC2-4A99-4CCE-B8DA-5F974FB946FDQ37136498-FA92E5AD-9D9F-40BC-BFA6-D35806E4EEDBQ37183155-EF2E50EF-5C3F-4D7D-8502-0258E62414FAQ37244144-E54CBD3C-DE59-41D1-9BEB-550D6DB3AC1DQ37316591-F760836B-8C0A-4A8F-A590-45967C194F12Q37328280-58DC9E1D-B730-429C-98DD-FF33075EAA1EQ37332223-4E9F7245-03B2-4A6D-8C8A-6E8099CCB38BQ37735773-99F44B1A-4949-4730-95A5-649B9AB50920Q37772026-54EA0C18-BD91-441F-96DC-3DB7EC8D783FQ37957892-BCA84FFB-1799-4FAB-BD80-DE3EBE6896B7Q39046334-6EE09DED-6308-4199-8D3D-B934FD795F6CQ39094862-FCD64FE0-9AC2-4778-BD42-EEA0792A43FEQ40476996-61BA40C0-5CE1-41A4-885B-73578E3D261FQ43058202-5DE26805-B96A-4397-AAD2-660E5756CEFCQ44529066-17DA4C76-D1A5-43FA-BE2E-E7EDA8EBAF2DQ44673491-B67EDD9C-9755-466A-87CF-D699F4042BC6Q44937008-DDB7ED80-3EE3-4330-B689-B8A076EE1F9EQ45877882-221D2F30-54C9-4030-B0C4-3BA2413CE44CQ48647228-A493C059-7DB6-469C-972B-A0A301898241Q51708707-C8CB1E72-ED9D-453C-B51F-00E92A74B2ACQ51993137-E4C0B3BD-01E4-4B40-98AC-3F8AE8A49C66Q58804939-880DE3C4-9E11-47C9-8A5A-D9F87A1AB609
P2860
Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS.
@en
Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS.
@nl
type
label
Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS.
@en
Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS.
@nl
prefLabel
Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS.
@en
Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS.
@nl
P2093
P356
P1433
P1476
Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS.
@en
P2093
Calabresi PA
Dhib-Jalbut S
McFarland HF
P304
P356
10.1212/WNL.51.1.289
P407
P577
1998-07-01T00:00:00Z